Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.

An all-female panel of medtech DEI leaders at the LSX Congress USA conference discussed the importance of diversity and inclusion in research, clinical trials, product development and services to advance health equity as well as fundamental business goals.

Parse Biosciences’ motion to dismiss a patent infringement case has been rejected by a US District Court.

The US FDA has updated its final guidance to clarify use of the Breakthrough Devices Program in advancing health equity. The voluntary program was created to speed up the process of getting innovative medical devices to patients that treat life-threatening or debilitating diseases.

Relievant’s Intracept intraosseous nerve ablation system is the only FDA-cleared neuromodulation device indicated to treat vertebrogenic pain. Boston Scientific will pay $850m for Relievant, plus undisclosed milestone payments over the next three years.

The UK-based company has just raised $165m support the ongoing commercialization of the Versius robotic platform.

Abbott and Bigfoot Biomedical have worked as partners for more than half a decade but will now continue as one. Analysts are questioning whether the merger will simply be a tuck-in for Abbott, or enable it to release an insulin pump of their own.

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights VR, AI and other high tech trends in rehabilitation and gait training. Hannah Daniel discusses cybersecurity updates such as the new NIST published draft for an updated version of the Cybersecurity Framework, a recent report by Health-ISAC, and an interview with MedCrypt’s Naomi Schwartz about the upcoming FDA cybersecurity regulations for premarket approvals.

China’s growing market for medtech, estimated at $70bn in 2021, could more than double this decade if the government’s Healthy China 2030 plan stays on track.  

Technical teams have laid the cornerstone for the platform that will be developed to link up multiple public and private data sources and make it easier to access, integrate and analyze the vast and diverse range of data they contain.

Not all PTAB changes floated in advanced notice of proposed rulemaking will be pursued, and the rule may be split into two, USPTO Director Vidal testifies. Industry groups criticize the proposals.

The major reform of Germany’s DRG payment system moved to the next stage after a federal-state working group delivered a key points document on 10 July. January 2024 remains the effective date for the system overhaul, which the government says meets health care budgetary and quality needs.

Bayer's head of R&D and chief scientific officer David Evendon-Challis talked to Medtech Insight about the company's prescision health business, including a holistic and personalized approach to digital self-care.

Pear Therapeutics filed for Chapter 11 bankruptcy in April and sold its remaining assets in an auction for about $6m. The demise of one the pioneers in the prescription digital therapeutics industry highlights the challenges PDT developers face getting their products reimbursed.

“There’s no one company, government, person or technology who is positioned to ‘solve’ the health of the world,” notes Haleon's Nick Tate. Which is why OTC companies are partnering with tech firms large and small to create the next generation of consumer healthcare products and services. In the first part of an exclusive interview on the future of digital consumer health, Tate – who heads up the firm’s incubator business, Haleon NEXT – discusses some of the complications of tech innovation that make such collaboration attractive.

In an event hosted by the Medical Device Innovation Consortium, cybersecurity experts discussed a benchmark report on the state of cybersecurity in the device industry. The director of digital health product security policy at Medtronic previewed the updated Joint Security Plan.

The genome-sequencing giant has named Jacob Thaysen, who brings extensive experience from Agilent, as its new leader.

Ivan Tornos will shift from COO to CEO of Zimmer Biomet now that former CEO Bryan Hanson has accepted the CEO job at 3M’s health care spinoff.

An interactive summary of recent executive-level company changes and promotions in the medical device and diagnostics sectors.

Against a globally tough environment, recruitment for EU medtech regulatory roles slowed down. Elemed’s Elena Kyria explains what is shaping talent hiring now there are signs of an uptick and how job seekers and recruiters can best position themselves